Researchers discovered genetic variants carried by roughly one in ten people that significantly reduce therapeutic response to popular GLP-1 diabetes medications. The finding may help explain why some patients experience limited benefit from widely prescribed drugs in this class.
GLP-1 receptor agonists have transformed type 2 diabetes and obesity treatment, but clinical practice includes notable non-responders. Genetic screening could eventually guide prescribing decisions for patients carrying the identified variants.
The study adds pharmacogenomics evidence to a drug category that includes semaglutide and similar agents used by millions worldwide. Understanding variant-linked resistance supports more personalized diabetes care.
Scientists emphasized that genetic factors represent one among several influences on drug efficacy, including diet, adherence, and comorbidities. Further research will examine whether dosing adjustments or alternative therapies better serve variant carriers.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/top/health/